- Pages
- 5
- Published in
- United States of America
A Phase Ii Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinaemia
2024
<Macro 'access_denied_modal'>
<Macro 'unauthorized_modal'>
Add to list
Citation
IWMF, 2024. A Phase Ii Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinaemia, IWMF: International Waldenstrom's Macroglobulinemia Foundation.
United States of America.
Retrieved from https://coilink.org/20.500.12592/1doz8ec on 15 Nov 2024. COI: 20.500.12592/1doz8ec.
Full-page Screenshot
